Esteban Vázquez, AnaCobo Ibáñez, María TatianaMora, GemaMuñoz Fernández, Santiago2024-07-082024-07-082023Esteban-Molina, A., Cobo-Ibanez, T., Mora, G., Vidal-Ortolá, M., Bayon-Garcia, C., & Munoz-Fernandez, S. (2023). Quick response to rituximab in a patient with Ro52-Jo1 complex-associated antisynthetase syndrome debuting with rapidly progressive interstitial lung disease and diffuse alveolar haemorrhage. Revista de Patología Respiratoria, 26(3), 11568. https://doi.org/10.24875/RPR.230000181576-98952173-920Xhttp://hdl.handle.net/11268/12949Antisynthetase syndrome (AAS) is an inflammatory myopathy that may debut with interstitial lung disease (ILD). A few studies show cases in which patients with high concentrations of anti-Ro52 in patients with ILD might achieve a better response if treated with Rituximab than other patients with ILD and Ro-52 whose levels are lower. We present a patient with lung involvement as the first and unique manifestation of AAS with anti-Jo and anti-Ro52-positive antibodies. The ILD was rapid and progressive and led him into the intensive care unit in a matter of days, despite several immunosuppressive treatments. As soon as the patient received this treatment, he experienced an improvement. We therefore suggest the prompt determination of anti-Ro52 antibody concentrations in this subgroup of patients, which would offer a therapeutic approach based first on rituximab over other immunosuppressive treatments.engAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/SintetasaEnfermedades Pulmonares IntersticialesAnticuerposjournal article10.24875/RPR.23000018open accessAparato respiratorioTratamiento médico